NAD+ Injection Therapy in Australia: What It Is and How to Access It Through a GP

Interest in NAD+ injection therapy has grown considerably in Australia over the past two years. Clinics in Brisbane, Sydney, and Melbourne now offer it as part of broader longevity and performance protocols. Telehealth services have made GP-prescribed access available nationally. Yet for many Australians, the basic questions remain unanswered: what is NAD+, what is the research examining it for, and how does prescription access actually work in this country?

This article covers those questions honestly — including what the evidence does and does not support.

What Is NAD+ and Why Do Levels Decline?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It plays a foundational role in cellular metabolism — specifically in the mitochondrial processes that generate adenosine triphosphate (ATP), the body's primary energy currency. NAD+ also participates in DNA repair mechanisms and supports cellular signalling pathways associated with healthy ageing research.

Levels of NAD+ naturally decline over time. Research has documented this decline as a consistent feature of ageing, with additional reductions observed in response to chronic illness, high physiological stress, and certain lifestyle factors. This has prompted significant scientific interest in whether restoring NAD+ levels could have measurable health effects.

Injectable NAD+ delivers the coenzyme subcutaneously or intravenously, bypassing the digestive process. Oral supplements — including NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — require conversion steps before the body can utilise them. The injectable route is the pathway practitioners cite when discussing direct cellular delivery, though head-to-head clinical comparison data between oral and injectable forms in humans remains limited.

What Is NAD+ Injection Therapy Being Studied For?

Research has explored NAD+'s potential role across a number of areas. It is important to frame these as active areas of scientific investigation rather than established therapeutic indications — no NAD+ injectable product is TGA-approved for any specific condition in Australia.

• Energy and metabolic function. Preclinical and early human research has investigated NAD+'s involvement in mitochondrial ATP production and its potential relevance to fatigue and metabolic regulation. Studies have examined its role in individuals experiencing burnout, persistent fatigue, and elevated physiological demand.
• Cognitive performance. NAD+ participates in neurotransmitter synthesis pathways. Research has examined its potential involvement in cognitive clarity, focus, and the neurological changes associated with ageing. These studies are largely observational or preclinical at this stage.
• Longevity science and cellular repair. A substantial body of research has focused on NAD+'s role in activating sirtuins — a family of enzymes implicated in DNA repair, gene expression, and cellular stress responses. This pathway is a central area of healthy ageing research, though translating these findings into clinical recommendations for humans remains an active area of investigation.
• Recovery and physical performance. Early research has examined NAD+'s involvement in muscle repair, exercise recovery, and markers of cellular resilience. Athletes and performance-focused individuals have shown significant interest in this area, though clinical evidence in healthy human subjects remains preliminary.

To be clear: these are research areas. A prescribing GP considers the current evidence base and the individual patient's clinical context when assessing whether NAD+ therapy is appropriate.

What Does the Science Say? An Honest Assessment for Australians

The scientific interest in NAD+ is genuine. Decades of research — predominantly preclinical and increasingly in early human studies — have documented its central role in cellular function and its decline with age. Institutions including Harvard, Columbia, and the Salk Institute have published extensively on NAD+ biology and the potential consequences of its depletion.

However, Australians should understand where the evidence stands:

• No TGA-approved NAD+ injectable product exists. Compounded injectable NAD+ in Australia is dispensed as a Schedule 4 prescription-only medicine under an off-label compounding framework through TGA-licensed pharmacies. This is the same pathway used for many other compounded medicines in integrative and preventative medicine.
• Most human data is early-stage. The most compelling mechanistic data comes from preclinical models. Human trials are ongoing but have not yet produced large-scale randomised controlled data that would meet the standard for a TGA-approved therapeutic indication.
• Long-term safety data in humans is limited. Injectable NAD+ is considered well-tolerated in short-term clinical use, with transient side effects — mild flushing, injection site discomfort, and occasionally nausea — reported in some users. Long-term safety profiles have not been established through large-scale clinical research.

This context does not mean NAD+ injection therapy is without clinical interest or merit. It means the decision to pursue it should be made with accurate information and a GP who understands the current evidence base.

NAD+ Injection vs Oral NAD+ Supplements — Is There a Difference?

Oral NAD+ precursors — primarily NMN and NR — have become popular supplements. These compounds are metabolised in the gut and converted into NAD+ through biochemical pathways. They are accessible without prescription and supported by a growing body of research.

Injectable NAD+ bypasses this conversion process. The rationale practitioners cite is direct systemic delivery, potentially offering greater reliability of bioavailability — particularly for individuals whose digestive function or metabolic conversion may be suboptimal. Whether injectable NAD+ offers clinically meaningful advantages over well-dosed oral precursors in healthy adults has not been established in head-to-head clinical trials. A GP assessing a patient for NAD+ support would consider the individual's goals, health status, and clinical history when determining the most appropriate route of administration.

Who Might a GP Consider NAD+ Therapy For?

Under the TGA framework, a GP prescribes compounded medicines on an individual, clinical basis. There is no approved indication for compounded NAD+ — the decision is entirely a clinical one made by the prescribing practitioner.

In practice, Australian GPs working in integrative and preventative medicine have explored NAD+ therapy in the context of:

• Adults experiencing persistent fatigue or reduced energy that has not responded to conventional approaches
• Adults interested in proactive longevity and cellular health support
• Individuals with cognitive changes associated with ageing or chronic physiological demand
• Those seeking structured, medically supervised support for performance and recovery

A GP at High Performance Human would assess your health history, goals, and clinical profile before determining whether NAD+ therapy is appropriate for you. Not everyone who enquires will be a suitable candidate — that assessment is the point of the consultation.

What Does a GP Consultation for NAD+ Look Like in Australia?

No referral is needed. No waitlists. Pricing for the Longevity Protocol — which may include NAD+ support — is published transparently on the HPH pricing page.

How to Access NAD+ Therapy Through High Performance Human

High Performance Human's Longevity Protocol is designed for adults who want structured, GP-supervised support for cellular health and healthy ageing. NAD+ support is one component of this protocol, determined by your GP based on your individual assessment.

Every protocol through HPH is reviewed and prescribed by a registered Australian GP, dispensed by a TGA-licensed Australian compounding pharmacy, priced transparently with no hidden fees, and reviewed at 12 weeks by your GP to assess progress and adjust if needed.

If you have been exploring NAD+ therapy and want to understand whether it is appropriate for your situation, the starting point is completing your health assessment. It takes five minutes. A GP will be in touch within 48 hours.

Understanding the Context Before You Start

NAD+ injection therapy sits at the intersection of genuine science, growing clinical interest, and an evidence base that is still maturing. The interest is not unfounded — the biological rationale is well-established, and the clinical community is paying attention. But Australians deserve accurate information about where the evidence currently stands, rather than marketing language that overstates what is known.

That is the standard High Performance Human holds itself to. GP-prescribed, compounding pharmacy-dispensed, and honest about what the research does and does not yet confirm. If you want to explore whether NAD+ therapy is right for you, a consultation with an Australian GP is the appropriate first step.

You may also find these related articles useful: what Epithalon is and how longevity peptides work, how to get peptides prescribed in Australia, how much peptide therapy costs, GP-prescribed vs grey market peptides, and what Australian GPs say about peptide safety.